Third Party Injection Manufacturing Company in India | Complete Guide

When a hospital pharmacist, institutional buyer, or international distributor searches for an injection manufacturing company in India, they are not browsing a catalogue. They are making a patient safety decision. A contaminated injectable doesn’t cause discomfort — it can end a life. That reality defines how the best injection manufacturing companies in India think, build, and operate.

This guide covers what genuinely separates a WHO-GMP certified sterile injectable manufacturer from a DCGI-registered facility that simply can’t supply to regulated markets. It explains 9M India’s credentials, infrastructure, therapeutic coverage, and documentation readiness — and answers every question a serious procurement partner should ask before signing.

9M India is a WHO-GMP certified injection manufacturing company in India with 177 million units annual capacity, 1,000+ approved formulations, and active export to 15+ countries. Every injectable batch is released from an in-house QC lab — no third-party testing gaps.

9M India at a Glance: Brand Credentials

Before going into the details of what makes injection manufacturing so technically demanding, here is what 9M India brings to the table — verifiable, auditable, and not marketing claims.

These are not aspirational targets. They are current, auditable facts — the kind procurement committees, tender evaluators, and regulatory inspectors verify.

Why Injection Manufacturing in India Is a Category of Its Own

Injectable pharmaceuticals are classified differently from oral dosage forms for one straightforward reason: they bypass the body’s natural defence systems. A contaminated tablet is unlikely to trigger a life-threatening event. A contaminated injection can — directly.

The WHO, India’s Central Drugs Standard Control Organisation (CDSCO/DCGI), and international procurement bodies such as UNICEF and the Global Fund all require documented proof of aseptic manufacturing, validated sterilisation processes, environmental monitoring, and batch-level analytical testing before injectables can be supplied.

For buyers, this translates to one guiding principle: never evaluate an injection manufacturing company in India purely on catalogue range or price. Evaluate on certification, infrastructure, and documentation — first.

Fewer than 18% of DCGI-registered pharmaceutical manufacturing plants in India hold WHO-GMP certification. The gap between ‘registered’ and ‘compliant’ is not bureaucratic — it is clinical and commercial risk.

9M India’s injectable manufacturing facility at Birkoni, Mahasamund, Chhattisgarh operates at the top of that 18% — with WHO-GMP certification specifically covering sterile injectable manufacturing, not just the broader oral formulation plant.

The Certification Hierarchy: What Actually Matters

WHO-GMP Certification

The international benchmark. Confirms that a facility’s processes, equipment, personnel, and documentation systems meet the World Health Organization’s Good Manufacturing Practice guidelines. For export to Africa, Southeast Asia, the Middle East, and SAARC — and for international institutional tenders — WHO-GMP is the minimum requirement. See 9M India’s Quality Commitment →

DCGI Approval (Drug Controller General of India)

Means each molecule manufactured at the facility has a valid product-specific manufacturing licence issued by the national regulator. A WHO-GMP certificate without DCGI-approved formulations is incomplete for domestic supply. 9M India holds product-specific DCGI approvals for all molecules in the injectable portfolio.

Cleanroom Classification: Grade A to Grade D

For injectables, the critical aseptic fill-finish zone must meet Grade A (ISO 5) under Grade B (ISO 7) background — a standard that requires investment in both facility design and continuous environmental monitoring programmes. 9M India’s injectable fill-finish area operates to this standard with documented environmental monitoring records available on request.

In-House QC Laboratory Accreditation

When a manufacturer issues a Certificate of Analysis from its own in-house QC lab — not a third-party facility — the chain-of-custody accountability for every batch is complete and traceable. 9M India’s QC lab conducts sterility testing, bacterial endotoxin testing (LAL test), particulate matter analysis, pH, assay, and related substance testing in-house.

What a World-Class Sterile Injectable Manufacturing Facility Looks Like

Infrastructure is the signal that separates a genuinely compliant injection manufacturing company in India from one operating within the gaps of a DCGI registration. Here is what to look for — and what 9M India has built:

• Classified cleanroom environments with continuous environmental monitoring (particulate counts, microbiological surface and air sampling, differential pressure records, gowning breach logs)
• Aseptic fill-finish capability in Grade A / ISO 5 clean zone under Grade B / ISO 7 background — for liquid vials, glass ampoules, and dry powder injections
• In-house sterility testing and LAL (bacterial endotoxin) testing — no chain-of-custody gaps from third-party lab outsourcing
• Container closure integrity testing on every batch — visible and sub-visible particulate matter analysis
• Cold chain storage across all temperature ranges: ambient (+15°C to +30°C), controlled room temperature (+15°C to +25°C), and refrigerated (+2°C to +8°C) with temperature excursion logging
• Full batch traceability — raw material CoA linkage through to finished goods release documentation

View 9M India’s manufacturing infrastructure: Our Infrastructure →

Injectable Product Portfolio: Therapeutic Coverage for Institutional Buyers

Institutional procurement — whether for government hospitals, central procurement agencies, NGOs, or international health programmes — typically requires depth across a core set of therapeutic categories. As a leading injection manufacturing company in India, 9M India covers all five critical verticals:

Analgesic & Pain Relief Injectables

Paracetamol injection is the most widely procured injectable in government and hospital supply chains. Available in liquid vial format (100ml/500ml), requiring stringent purity, pyrogen, and bacterial endotoxin controls. Also covers NSAIDs (Ketorolac, Diclofenac) for post-surgical and acute pain management.

Explore Pain Management Products →

Anaesthetic Injectables

Local anaesthetics (Lidocaine, Ropivacaine) in ampoule format and general anaesthetics (Propofol) in vial format. These require strict stability, sterility, and pyrogen controls — and the ability to manufacture under conditions that prevent cross-contamination.

Cardiovascular Injectables

Critical care staples: Heparin (anticoagulant), Labetalol (antihypertensive), Adenosine (antiarrhythmic). These molecules appear in ICU and emergency department formularies worldwide and represent high-stakes supply chain items where a shortfall is not tolerated.

Explore Cardiovascular Products →

Gastrointestinal Injectables

Ondansetron (anti-emetic in liquid vial), Pantoprazole (proton pump inhibitor in dry powder format requiring reconstitution), and Methylprednisolone (corticosteroid). All three appear on most essential medicines lists and WHO procurement programmes.

Explore Gastrointestinal Products →

Anti-Infective & Anti-Inflammatory Injectables

Dexamethasone (corticosteroid, anti-inflammatory), Amikacin and Gentamicin (aminoglycoside antibiotics), and Ceftriaxone (third-generation cephalosporin in dry powder format). These cover post-operative care, sepsis management, and respiratory infection treatment.

Explore Anti-Infective Products →  |  Explore Antibiotics →

Documentation: The Factor That Decides Tender Outcomes

In institutional and government pharmaceutical procurement, documentation determines whether a bid is accepted or disqualified — often before the evaluation committee looks at pricing. A procurement-ready injection manufacturing company in India should be able to provide the following within 24 hours of request:

• Certificate of Analysis (COA) — batch-specific analytical results from the in-house QC laboratory
• Certificate of Conformance (COC) — confirming the batch meets all specification requirements
• WHO-GMP Certificate — current, facility-specific, covering sterile injectable manufacturing
• DCGI Manufacturing Licence — product-specific, confirming legal authorisation to manufacture each molecule
• Stability Data — ICH conditions (25°C/60% RH for Zone II, 30°C/65% RH for Zone IVa), confirming shelf-life claims
• Process Validation Reports — reproducibility demonstrated across three or more commercial-scale batches
• Product Dossiers for Export Registration — formatted for target country regulatory submission requirements

9M India has this documentation pre-archived, version-controlled, and available within 24 hours. For buyers working against tender submission deadlines, this is a material operational advantage — not a marketing claim.

Request Documentation Package →

Why 9M India Is Different: The Differentiators That Matter

Many facilities describe themselves as a leading injection manufacturing company in India. Here is what separates a claim from a capability:

Related reading: What Separates a Compliant Supplier from a Risky One →

Brand Reputation: What 200+ Global Clients Are Telling Us

9M India’s reputation is not built on marketing. It is built on verifiable performance across six measurable dimensions:

1. Export Track Record Across 15+ Countries

Active export to Sierra Leone, Uganda, the UAE, and multiple African and Middle Eastern markets — all requiring the most stringent documentation and compliance proof before a single unit crosses the border.

2. Institutional Tender Supply Experience

Demonstrated capability to supply CGHS, ESIC, and state government tender programmes — with full bid documentation prepared and submitted within institutional deadlines. See Institutional Tender Services →

3. WHO-GMP Certification Achieved in 2022

Achieving WHO-GMP certification within two years of commencing operations is a marker of management seriousness about quality — not a checkbox pursued years after commercial launch.

4. 1,000+ Approved Formulations

Across tablets, capsules, syrups, suspensions, ointments, creams, gels, eye drops, ear drops, and injectables — 9M India functions as a single-source pharmaceutical manufacturer for partners who need breadth without sacrificing depth. Explore the Full Product Range →

5. Transparent Leadership Team

Managing Director Mr. Manish Agrawal, Directors Mr. Ashish Agrawal, Mr. Ajay Agrawal, and Mr. Rachit Agrawal — names and responsibilities publicly available, not a faceless corporate entity.

6. 700+ Professional Team at a Single Site

Manufacturing, QA/QC, regulatory affairs, logistics, and customer service under one roof at Birkoni. No outsourcing, no accountability gaps, no ‘that’s a different department’ delays. Why 9M India →

Why India Is the Right Source for Injection Manufacturing

India accounts for approximately 20% of global generic medicine exports by volume and supplies over 60% of the WHO’s vaccine requirements. The Indian pharmaceutical industry’s cost efficiency, regulatory infrastructure, and manufacturing depth make it the preferred source for injectable medicines across Asia, Africa, the Middle East, and beyond.

However, the key qualifier is compliance. Fewer than 18% of Indian pharmaceutical manufacturing plants hold WHO-GMP certification. The gap between a registered manufacturer and a compliant one is significant — and it is the buyer’s risk to manage if the wrong choice is made.

Choosing a WHO-GMP certified injection manufacturing company in India with documented export history, institutional tender capability, and in-house quality release is the only way to manage that risk systematically.

Related reading: Navigating Global Challenges in Pharmaceutical Manufacturing →  |  What Happens Before Medicines Reach the Market →

Third Party & Contract Manufacturing for Injections

9M India operates as a full-service third-party and contract injection manufacturing company in India — handling formulation development, aseptic manufacturing, quality release, and regulatory documentation for partner brands.

Whether you need white-label injection manufacturing for your domestic brand or export-branded products registered in international markets, 9M India’s contract manufacturing infrastructure supports the full cycle:

• Formulation development support — molecule-specific stability and compatibility studies
• Aseptic fill-finish under WHO-GMP compliant conditions
• Full in-house quality release — COA, COC, and batch release documentation
• Product registration dossier preparation for target markets
• Private label and export branding capability

Learn About Third-Party Manufacturing →  |  Contract Manufacturing →

Regulatory Support: From India to International Markets

Getting a product manufactured is only half the challenge for international buyers. Registering that product in the destination country — and maintaining that registration through product lifecycle management — is where many injection manufacturers in India fall short.

9M India’s regulatory services capability covers:

• DCGI dossier preparation and submission support for India
• Export registration dossiers formatted for African, Middle East, and SAARC regulatory frameworks
• CTD (Common Technical Document) formatting for regulated market submissions
• Post-approval change management — variation filing support

Explore Regulatory Services →

Global Presence: Where 9M India Supplies

9M India’s injectable products are currently supplied to buyers in 15+ countries, with active market presence across:

• West Africa: Sierra Leone, Uganda
• Middle East: UAE and Gulf Cooperation Council (GCC) markets
• South Asia: SAARC-region institutional and government procurement
• India: domestic hospital, institutional, and government tender supply

Global expansion is supported by export-formatted regulatory dossiers and the WHO-GMP certificate that most international tendering bodies require as a minimum qualification. View Our Global Presence →

Buyer Checklist: How to Evaluate Any Injection Manufacturing Company in India

Before placing an order or signing a contract manufacturing agreement with any injection manufacturer in India, verify the following:

• Is the WHO-GMP certificate current, facility-specific, and covering sterile injectable manufacturing? (Request the certificate — not just a claim)
• Are the molecules you need DCGI-approved at this facility? (A WHO-GMP plant without product-specific licences cannot legally supply those products)
• Does the facility have in-house sterility and endotoxin testing? (Third-party testing introduces chain-of-custody gaps)
• Can documentation (COA, COC, stability data, dossiers) be provided within your tender deadline? (Test this before you need it)
• Does the manufacturer have documented export history? (This is the strongest external validation of regulatory acceptance)
• Is cold chain capability available and documented for temperature-sensitive molecules?
• What is the minimum order quantity (MOQ)? Does it match your volume requirements?
• Is the regulatory dossier support in-house — or outsourced to a consultant?

9M India satisfies all eight criteria — and can provide documentary evidence for each within 24 hours. Request a verification pack at info@9mindia.in

Related Reading: Topical Authority on Injection Manufacturing

9M India’s blog covers the full knowledge landscape that buyers, distributors, and partners need to navigate injectable pharmaceutical manufacturing in India:

Top 10 Injection Manufacturers in India (2026) — Certified →

A comprehensive comparison of India’s leading certified injection manufacturers — their certifications, therapeutic coverage, export capability, and compliance status.

Injection Manufacturer in India: Compliant vs Risky Supplier →

Practical guide to the specific certifications, infrastructure elements, and documentation that separate a reliable injectable partner from a compliance liability.

The Challenges Behind Every Batch →

Inside the quality control decisions that happen before any pharmaceutical batch is approved for release — from raw material receipt to final QC sign-off.

Navigating Global Challenges in Pharmaceutical Manufacturing →

How Indian pharma manufacturers are responding to supply chain disruptions, regulatory tightening, and rising global demand for quality-compliant generics.

What Happens Before Medicines Reach the Market →

The complete pre-market journey of a pharmaceutical product — from formulation development through stability trials, regulatory submission, and commercial launch.

Whom to Trust When There’s No Room for Error? →

A practical framework for evaluating pharmaceutical manufacturing partners in high-stakes procurement situations — including injectable supply for hospital and government use.

Frequently Asked Questions: Injection Manufacturing Company in India

Q1. What is the difference between a WHO-GMP certified injection manufacturing company and a standard DCGI-registered one?

DCGI registration confirms that a facility is permitted to manufacture pharmaceuticals in India under domestic law. WHO-GMP certification goes further — it confirms the facility has been independently audited against the World Health Organization’s international quality standards, which are required for export to most regulated and semi-regulated markets globally. For any institutional, export, or government tender buyer, WHO-GMP is the minimum acceptable standard. 9M India holds WHO-GMP certification specifically covering its sterile injectable manufacturing operations.

Q2. What types of injectable formulations does 9M India manufacture?

9M India manufactures Small Volume Parenterals (SVP) in three container formats: (a) liquid vials — single and multi-dose, (b) glass ampoules, and (c) dry powder injections requiring reconstitution at point of use. The therapeutic portfolio covers analgesic/pain relief, anaesthetic, cardiovascular, gastrointestinal, anti-inflammatory, and anti-infective categories. Key molecules include Paracetamol, Propofol, Lidocaine, Heparin, Ondansetron, Pantoprazole, Dexamethasone, Ketorolac, Amikacin, and Ceftriaxone.

Q3. Can 9M India supply injectables for government tenders and institutional procurement?

Yes. 9M India has active experience supplying CGHS, ESIC, and state government tender programmes. All products are DCGI-approved for the relevant molecules. The full documentation package — including COA, COC, manufacturing licence, WHO-GMP certificate, and stability data — is pre-prepared and deliverable within 24 hours for tender bid submission.

Q4. Does 9M India offer third-party and contract injection manufacturing?

Yes. 9M India offers end-to-end third-party and contract manufacturing for injectable formulations. This covers formulation development, aseptic manufacturing under WHO-GMP conditions, full in-house quality release, private label branding, and export registration dossier support. Contact the team at info@9mindia.in or +91 9900095000 to discuss requirements.

Q5. What documentation is provided with each injectable batch for export?

Each exported batch is accompanied by: Certificate of Analysis (COA) and Certificate of Conformance (COC) from the in-house QC laboratory. Additional documentation — including stability study data (ICH conditions), process validation reports, product dossiers, DCGI manufacturing licences, and WHO-GMP certificates — is available within 24 hours of request.

Q6. How does 9M India ensure sterility in its injectable manufacturing operations?

Sterility is maintained through: (a) classified cleanroom environments — aseptic fill-finish under Grade A / ISO 5 conditions within Grade B / ISO 7 background; (b) validated sterilisation and aseptic processes with periodic revalidation; (c) continuous environmental monitoring — particulate and microbiological; (d) container closure integrity testing on every batch; (e) in-house sterility testing and LAL (bacterial endotoxin) testing before batch release. Nothing is released before the in-house QC lab signs off.

Q7. Which countries does 9M India currently export injectable products to?

9M India exports to 15+ countries, with active presence in West Africa (Sierra Leone, Uganda), the UAE, and other Middle Eastern and SAARC markets. WHO-GMP certification enables participation in international procurement tenders and supply to global health organisations.

Q8. What is the minimum order quantity (MOQ) for injectable products at 9M India?

The domestic MOQ for injections is 1 Lakh (1,00,000) units. Export order quantities are discussed based on molecule, container format, pack size, and destination market logistics. Contact info@9mindia.in or +91 9900095000 for a tailored product list and volume options within 24 hours.

Q9. Does 9M India manufacture both liquid vials and dry powder injections?

Yes. 9M India’s injectable manufacturing capability covers all three Small Volume Parenteral (SVP) formats: liquid vials (single and multi-dose, including large volume parenterals), glass ampoules, and dry powder injections requiring reconstitution — such as Pantoprazole and Ceftriaxone. This makes 9M India a single-source partner for buyers needing multiple injectable formats.

Q10. What is 9M India’s annual manufacturing capacity for injections?

9M India’s total annual pharmaceutical manufacturing capacity is 177 million units across all formulation types. Injectable-specific capacity figures are available on direct enquiry, as they vary by container format and molecule complexity. The facility is designed for large-scale, scalable production with regulatory compliance maintained at every batch size.

Q11. Is 9M India listed on any international procurement platforms?

9M India participates in institutional tender supply processes for government and NGO buyers. For specific registration on international procurement platforms (UNGM, WHO prequalification pipelines), buyers can contact the regulatory affairs team directly via info@9mindia.in.

Q12. What makes 9M India different from other injection manufacturing companies in India?

The three differentiators that matter most to serious buyers: (a) WHO-GMP certification specifically covering sterile injectable manufacturing — not a generic plant-wide certification; (b) 100% in-house QC  sterility, endotoxin, particulate matter, and assay testing from 9M India’s own accredited laboratory; (c) 24-hour documentation turnaround COA, COC, stability data, DCGI licences, and WHO-GMP certificates all pre-archived and ready.

Partner with 9M India — India’s WHO-GMP Certified Injection Manufacturing Company

India is the world’s most cost-efficient source of quality injectable medicines. But cost efficiency is only valuable when it comes with WHO-GMP certification, DCGI product approvals, in-house QC, and documentation ready within 24 hours.

9M India has built its injectable manufacturing operation around the buyer’s reality not the manufacturer’s convenience.